litlas
ログインアカウント作成

Elise C. Kohn

1988–2025 年に発表

110
論文数
23,229
被引用数
81
h 指数
104
i10 指数

被引用数

Elise C. Kohn の年別被引用数1964 年: 被引用 1 件1987 年: 被引用 1 件1988 年: 被引用 1 件1989 年: 被引用 2 件1990 年: 被引用 7 件1991 年: 被引用 6 件1992 年: 被引用 19 件1993 年: 被引用 26 件1994 年: 被引用 57 件1995 年: 被引用 38 件1996 年: 被引用 43 件1997 年: 被引用 67 件1998 年: 被引用 55 件1999 年: 被引用 58 件2000 年: 被引用 63 件2001 年: 被引用 70 件2002 年: 被引用 172 件2003 年: 被引用 259 件2004 年: 被引用 338 件2005 年: 被引用 341 件2006 年: 被引用 288 件2007 年: 被引用 217 件2008 年: 被引用 189 件2009 年: 被引用 160 件2010 年: 被引用 176 件2011 年: 被引用 143 件2012 年: 被引用 148 件2013 年: 被引用 121 件2014 年: 被引用 143 件2015 年: 被引用 170 件2016 年: 被引用 164 件2017 年: 被引用 169 件2018 年: 被引用 162 件2019 年: 被引用 598 件2020 年: 被引用 612 件2021 年: 被引用 631 件2022 年: 被引用 505 件2023 年: 被引用 377 件2024 年: 被引用 503 件2025 年: 被引用 249 件2026 年: 被引用 6 件1965〜1986 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,697 件、この内訳の 28.9%中国: 引用元論文 1,190 件、この内訳の 12.7%イギリス: 引用元論文 570 件、この内訳の 6.1%イタリア: 引用元論文 520 件、この内訳の 5.6%ドイツ: 引用元論文 396 件、この内訳の 4.2%カナダ: 引用元論文 328 件、この内訳の 3.5%フランス: 引用元論文 276 件、この内訳の 3%日本: 引用元論文 263 件、この内訳の 2.8%オーストラリア: 引用元論文 243 件、この内訳の 2.6%スペイン: 引用元論文 215 件、この内訳の 2.3%インド: 引用元論文 214 件、この内訳の 2.3%オランダ: 引用元論文 192 件、この内訳の 2.1%
0%28.9%その他 23.9%

機関

分野

  • Medicine42.2%
  • Biochemistry, Genetics and Molecular Biology38.8%
  • Chemistry7.8%
  • Immunology and Microbiology3%
  • Computer Science2.8%
  • Neuroscience1.5%
  • その他3.9%

トピック

  • Ovarian cancer diagnosis and treatment4.8%
  • PARP inhibition in cancer therapy4.1%
  • Advanced Proteomics Techniques and Applications3%
  • Gene expression and cancer classification1.9%
  • DNA Repair Mechanisms1.9%
  • Angiogenesis and VEGF in Cancer1.6%
  • その他82.7%

共著者

全論文

検索で開く
  1. Ovarian cancer

    著者: Gordon C. Jayson, Elise C. Kohn, Henry C Kitchener, Jonathan A. Ledermann - The Lancet 2014 被引用: 1,873

  2. The MAPK pathway across different malignancies: A new perspective

    著者: Mauricio Burotto, Victoria L. Chiou, Jung‐Min Lee, Elise C. Kohn - Cancer 2014 被引用: 985

  3. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

    著者: Panagiotis A. Konstantinopoulos, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle, Elizabeth K. Lee, Elise C. Kohn, Linda Duska, Marta A. Crispens, Alexander Olawaiye, Ira Winer, Lisa Barroilhet, Siqing Fu, Michael McHale, Russell J. Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne Quinn, Brittany Bowes, Alan D. D’Andrea, Geoffrey I. Shapiro, Ursula A. Matulonis - The Lancet Oncology 2020 被引用: 232

  4. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

    著者: William P. Tew, Christina Lacchetti, Annie Ellis, Kathleen Maxian, Susana Banerjee, Michael A. Bookman, Monica B. Jones, Jung‐Min Lee, Stéphanie Lheureux, Joyce F. Liu, Kathleen N. Moore, Carolyn Y. Muller, Patricia Rodríguez, Christine Walsh, Shannon N. Westin, Elise C. Kohn - Journal of Clinical Oncology 2020 被引用: 310

  5. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    著者: Ignace Vergote, Antonio González-Martı́n, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Jean‐Emmanuel Kurtz, Aikou Okamoto, Kathleen N. Moore, Frédéric Kridelka, Iain A. McNeish, Alexander Reuß, Bénédicte Votan, Andreas du Bois, Sven� Mahner, I. L. Ray-Coquard, Elise C. Kohn, Jonathan S. Berek, David S.P. Tan, Nicoletta Colombo, Rongyu Zang, Nicole Concin, Dearbhaile M. O’Donnell, Alejandro Rauh-Hain, C. Simon Herrington, Christian Marth, Andrés Poveda, Keiichi Fujiwara, Gavin Stuart, Amit M. Oza, Michael A. Bookman, Sven� Mahner, Alexander Reuß, Andreas du Bois, Christoph Grimm, Christian Marth, Regina Berger, Nicole Concin, Ting‐Chang Chang, Kazunori Ochiai, Val Gebski, Alison Davis, Philip Beale, Ignace Vergote, Frédéric Kridelka, Hannelore Denys, Vincent Vandecaveye, Francisco José Cândido dos Reis, Maria Del Pilar Estevez-Diz, Gavin Stuart, Helen Mackay, Mark S. Carey, David Cibula, Pavel Dundr, Oliver Dorigo, Jonathan S. Berek, Dearbhaile M. O’Donnell, Feras Abu Saadeh, Ingrid Boere, Christianne Lok, Pluvio Coronado, Nelleke Ottevanger, David S.P. Tan, Joseph Ng, Antonio Gonzalez Martin, Ana Oaknin, Andrés Poveda, Alejandro Perez Fidalgo, Alejandro Rauh-Hain, Karen H. Lu, Carlos López-Zavala, Eva María Gómez-García, Isabelle Ray-Coquard, Xavier Paolettí, Jean‐Emmanuel Kurtz, Florence Joly, Bénédicte Votan, Michael A. Bookman, Kathleen Moore, Rebecca C. Arend, Keiichi Fujiwara, Hiroyuki Fujiwara, Kosei Hasegawa, Ilan Bruchim, Dalia Tsoref, Katsutoshi Oda, Aikou Okamoto, Takayuki Enomoto, Dayana Michel, Hee‐Seung Kim, Jung‐Yun Lee, Asima Mukhopadhyay, Dionyssios Katsaros, Nicoletta Colombo, Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Elise C. Kohn, Jungmin Lee, Iain A. McNeish, Shibani Nicum ほか 16 名 - The Lancet Oncology 2022 被引用: 142

  6. Use of proteomic patterns in serum to identify ovarian cancer

    著者: Emanuel F. Petricoin, Ali M. Ardekani, Ben A. Hitt, Peter J. Levine, Vincent A. Fusaro, Seth M. Steinberg, Gordon B. Mills, Charles B. Simone, David A. Fishman, Elise C. Kohn, Lance A. Liotta - The Lancet 2002 被引用: 3,256

  7. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

    著者: Panagiotis A. Konstantinopoulos, Barbara M. Norquist, Christina Lacchetti, Deborah K. Armstrong, Rachel N. Grisham, Paul J. Goodfellow, Elise C. Kohn, Douglas A. Levine, Joyce F. Liu, Karen H. Lu, Dorinda Sparacio, Christina M. Annunziata - Journal of Clinical Oncology 2020 被引用: 379

  8. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

    著者: Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Maria J. Merino, Elizabeth M. Swisher, Maria I. Harrell, Jane B. Trepel, Min-Jung Lee, Mohammadhadi Bagheri, Dana‐Adriana Botesteanu, Seth M. Steinberg, Lori M. Minasian, Irene Ekwede, Elise C. Kohn - The Lancet Oncology 2018 被引用: 212

  9. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update

    著者: William P. Tew, Christina Lacchetti, Elise C. Kohn, for the PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel - Journal of Clinical Oncology 2022 被引用: 114

  10. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

    著者: Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, David Cella, William P. Tew, Noelle G. Cloven, Carolyn Y. Muller, David P. Bender, Richard G. Moore, David P. Michelin, Steven E. Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman - Journal of Clinical Oncology 2022 被引用: 87

  11. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

    著者: Joyce F. Liu, William T. Barry, Michael J. Birrer, Jung Min Lee, Ronald J. Buckanovich, Gini F. Fleming, B.J. Rimel, Mary K. Buss, Sreenivasa Nattam, Jean Hurteau, Weixiu Luo, Philippa Quy, Christin Whalen, Lisa Obermayer, Hang Lee, Eric P. Winer, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis - The Lancet Oncology 2014 被引用: 584

  12. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

    著者: Jung Min Lee, Ashley Cimino‐Mathews, Cody J. Peer, Alexandra S. Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Liang Cao, Maria I. Harrell, Elizabeth M. Swisher, Nicole Houston, Dana‐Adriana Botesteanu, Janis M. Taube, Elizabeth Thompson, Aleksandra Ogurtsova, Haiying Xu, Jeffers Nguyen, Tony W. Ho, William D. Figg, Elise C. Kohn - Journal of Clinical Oncology 2017 被引用: 240

  13. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

    著者: J.F. Liu, William T. Barry, Michael J. Birrer, J.-M. Lee, Ronald J. Buckanovich, Gini F. Fleming, B.J. Rimel, Mary K. Buss, Sreenivasa Nattam, Jean Hurteau, Wenjie Luo, Jennifer Curtis, C. Whalen, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis - Annals of Oncology 2019 被引用: 189

  14. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

    著者: Jennifer A. Chan, Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher, Fang‐Shu Ou, Amylou C. Dueck, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj, Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt - New England Journal of Medicine 2024 被引用: 136

  15. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

    著者: Panagiotis A. Konstantinopoulos, Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro - Nature Communications 2021 被引用: 68

  16. Vaccination of Adults With Cancer: ASCO Guideline

    著者: Mini Kamboj, Kari Bohlke, Deana M. Baptiste, Kieron Dunleavy, Abbey Fueger, Lee Jones, Amar H. Kelkar, Lisa Y. Law, Kristine B. LeFebvre, Per Ljungman, Eric D. Miller, Larissa A. Meyer, Heather Moore, Heloisa P. Soares, Randy Taplitz, Edom Seife Woldetsadik, Elise C. Kohn - Journal of Clinical Oncology 2024 被引用: 108

  17. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

    著者: Stéphanie Lheureux, Zhongwu Lai, Brian Dougherty, Sarah Runswick, Darren Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David D.L. Bowtell, Elise C. Kohn, Clare L. Scott, Ursula A. Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O’Connor, Jane Robertson, Jonathan A. Ledermann, J. Carl Barrett, Tony W. Ho, Amit M. Oza - Clinical Cancer Research 2017 被引用: 154

  18. The microenvironment of the tumour–host interface

    著者: Lance A. Liotta, Elise C. Kohn - Nature 2001 被引用: 2,333

  19. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)

    著者: Jennifer A. Chan, Susan M. Geyer, F-S. Ou, Michael V. Knopp, Spencer C. Behr, Tyler Zemla, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos, Bhavana Konda, N. Vijayvergia, N.A. Dasari, J. Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt - Annals of Oncology 2023 被引用: 27

  20. New strategies in ovarian cancer treatment

    著者: Jung‐Min Lee, Lori M. Minasian, Elise C. Kohn - Cancer 2019 被引用: 121

  21. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

    著者: J.-M. Lee, Jonathan A. Ledermann, Elise C. Kohn - Annals of Oncology 2013 被引用: 356

  22. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

    著者: David A. Wheeler, Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton, Peter W. Laird, Linghua Wang, Adrienne Johnson, Ninad Dewal, Vincent A. Miller, David Piñeyro, Manuel Castro de Moura, Manel Esteller, Hui Shen, Jean C. Zenklusen, Roy Tarnuzzer, Lisa M. McShane, James V. Tricoli, P. Mickey Williams, Irina A. Lubensky, Geraldine O’Sullivan Coyne, Elise C. Kohn, Richard F. Little, Jeffrey D. White, Shakun Malik, Lyndsay N. Harris, Carol J. Weil, Alice P. Chen, Chris Karlovich, Brian Rodgers, Lalitha Shankar, Paula Jacobs, Tracy S. Nolan, Hai Hu, Donna M. Muzny, HarshaVardhan Doddapaneni, Viktoriya Korchina, Julie M. Gastier‐Foster, Jay Bowen, Kristen Leraas, Elijah F. Edmondson, James H. Doroshow, Barbara A. Conley, S. Percy Ivy, Louis M. Staudt - Cancer Cell 2020 被引用: 104

  23. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

    著者: Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel J. Robbie, Robert J. Lechleider - Investigational New Drugs 2012 被引用: 117

  24. Neuroendocrine Tumors—Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence

    著者: Aman Chauhan, Elise C. Kohn, Jaydira Del Rivero - JAMA Oncology 2019 被引用: 75